Affect and post-COVID-19 symptoms in daily life: An exploratory

experience sampling study 2

- 3 Gerko Schaap^{1*}, Marleen Wensink¹, Carine J. M. Doggen^{2,3}, Job van der Palen^{4,5}, Harald E.
- 4 Vonkeman^{1,6}, and Christina Bode¹
- ¹ Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands 6
- 7 ² Department of Health Technology and Services Research, Technical Medical Centre, University of
- 8 Twente, Enschede, The Netherlands
- 9 ³ Clinical Research Centre, Rijnstate Hospital, Arnhem, The Netherlands
- 10 ⁴ Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands
- 11 ⁵ Section of Cognition, Data and Education, University of Twente, Enschede, The Netherlands
- 12 ⁶ Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The
- 13 Netherlands

14

17

1

5

- 15 *Corresponding author
- 16 E-mail: g.schaap@utwente.nl (GS)

Abstract

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

Insight into the daily life experiences of patients with post-COVID-19 syndrome is lacking. The current study explored temporal fluctuations of and associations between positive and negative affect and symptoms throughout the day in previously hospitalised post-COVID-19 patients using an experience sampling methodology. Ten participants (age: median = 60, interquartile range = 9 years; 50% women; 80% ≥1 comorbidity; 8–12 months since hospital discharge) filled out brief online questionnaires, six times a day for 14 consecutive days. Positive and negative affect, and self-reported symptoms (physical and mental fatigue, cognitive functioning, dyspnoea, and pain) were assessed in real-time. Primarily, graphs were analysed to assess the individual longitudinal courses of and (concurrent and time-lagged) associations between affect and symptoms. Secondly, correlations or multilevel linear regression models were used to support these interpretations. Visual assessment showed limited temporal fluctuation in affect and symptoms. All symptoms appeared to associate positively with each other (correlations between .26 and .85). Positive affect was associated with lower symptoms severity (B's between -.28 and -.67), and negative affect with higher symptoms severity (B's between .24 and .66). Time-lagged analyses showed that – adjusted for residual symptom severity of prior measurements – both types of affect predicted symptom severity two hours later (β's between -.09 and -.31 for positive affect; between .09 and .28 for negative affect). These findings suggest that positive and negative affect may play important roles in post-COVID-19 symptom experience and temporal fluctuation.

- Keywords: Post-COVID-19 syndrome; long COVID; symptoms; affect; Experience Sampling
- 39 Methodology; Ecological Momentary Assessment

Introduction

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

While most people recover from a SARS-CoV-2 infection, a substantial group struggles with persistent symptoms. These sequelae are often referred to as long-COVID or as post-COVID-19 syndrome, which can be defined as "signs and symptoms that developed during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis" [1]. Estimated prevalence ranges between 6 to 45 percent of COVID-19 survivors [2-4], depending on definitions, populations, vaccination status, and SARS-CoV-2 variants within these samples. Most frequently reported post-COVID-19 symptoms include fatigue, cognitive dysfunction or brain fog, respiratory problems such as dyspnoea (breathlessness), chronic pain, and loss of sense of smell; often co-occurring [3, 5-9]. Previous research is mostly limited to cross-sectional or cohort studies, and few studies looked into the severity of these symptoms, their daily fluctuations, and the interrelations between these symptoms. Similarly, while reviews [6, 8] and qualitative studies [10-13] reported the effects on mental health and health-related quality of life, the daily fluctuations over time of positive and negative affect in post-COVID-19 patients have not yet been investigated.

Affect may play an important role in the severity, daily course, and potentially management of post-COVID-19 symptoms. One relevant framework to understand the associations between affect and symptoms is the Broaden-and-Build theory of positive emotions [14, 15]. Negative emotions narrow patients' attention and behaviours towards specific action tendencies necessary for survival, such as fear evoking an urge to escape [16]. In contrast, positive emotions can broaden patients' perspectives and approaches and help build personal physical, cognitive, social and psychological resources [14]. For health, this translates into the risk for negative affect to restrict one's attention on symptoms, whereas positive affect may help patients to find additional resources to cope with their symptoms and aid with self-management in general. This relationship between affect and symptoms has been found in many patient populations, and the directions of these relationships can be surprising; while it seems common sense that negative affect follows from increased symptom severity, the reverse can also be true. Both negative and positive affect have been found to be bidirectionally associated with or predictive of chronic symptoms such as fatigue, dyspnoea, and pain in various patient populations [17-22]. These

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

studies mostly made use of cross-sectional designs and investigated these relations at a trait level or relatively stable level, and hence provide little insight into short-term associations. In addition, investigating whether affect informs an increase or decrease of symptom severity shortly later allows for a richer, more detailed and nuanced understanding of illness experiences on a daily level. Moreover, this understanding may guide in identifying opportunities for more advanced interventions; advanced in the sense of potential for tailoring and personalisation. Currently it is not known whether positive and negative affect are predictive of post-COVID-19 symptoms, and how these are experienced real-time over the day.

To address the gaps in current knowledge, this observational study aimed to explore the daily courses of and interrelations between positive and negative affect and post-COVID-19 symptom severity, such as of fatigue, cognitive dysfunction, dyspnoea, and pain. An Experience Sampling Methodology (ESM) has been applied, which allowed investigating these aspects in daily life through repeated real-time assessments. Moreover, this method helps overcome recall bias, and due to the repeated observations within participants, allows for rich and robust insights in patients' daily experiences, even in small patient samples [23]. The following research questions were to assess: (1) temporal fluctuations of affect and post-COVID-19 symptoms; (2) whether these symptoms were associated with (a) positive and (b) negative affect measured concurrently; and (3) whether symptoms were predicted by (a) positive and (b) negative affect measured at an earlier timepoint using time-lagged analyses.

Methods

Recruitment

This study is part of a larger, on-going cohort study on the long-term impact of severe COVID-19 requiring hospitalisation (registered at ClinicalTrials.gov; NCT05813574). For the present study, participants were selected based on self-reported health status three months after hospital discharge and their self-assessed health status at the time of recruitment. Formerly hospitalised COVID-19 patients who indicated their health to be much worse compared to a year ago on the Dutch Short Form Health

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Survey (SF-36)[24] were selected for an interview [13]. During the interview, approximately 9 months after hospital discharge, self-perceived health status was reassessed, and participants were screened for symptoms (e.g. fatigue). If participants still suffered from post-COVID-19-associated symptoms, they were invited for the present study. Out of the 16 selected candidates, 11 were willing to participate.

Inclusion criteria were: a) having been discharged from hospital after polymerase chain reactionconfirmed acute COVID-19; b) persisting, fluctuating symptoms attributed by the participant to post-COVID-19 syndrome; c) ≥18 years of age; d) proficiency in Dutch; and e) willingness to install a smartphone-based measurement app. Participants were excluded from analysis in case of compliance rates <30% of the daily assessments [23]. All participants provided written informed consent, and the Medisch Spectrum Twente Institutional Review Board (K20-30) and the Ethics Committee Behavioural, Management and Social Sciences of the University of Twente, the Netherlands (210799) approved the study.

Procedure and measurements

Using an ESM setup, this study set out to examine daily fluctuations of and associations between affect and post-COVID-19 symptom severity. Data were collected between September 5 and October 27, 2021, using the Ethica platform (ethicadata.com) and the related Ethica smartphone application. ESM data consisted of daily questionnaires on symptoms, feelings, and behaviours. Additional data were collected, but were beyond the scope of this study and are discussed elsewhere [25]. See Appendix S1 for the complete questionnaires in Dutch (original) and English (translated). Demographic and health-related characteristics were retrieved from hospital medical records with participants' approval. Participants were followed for 14 consecutive days via seven daily self-report questionnaires prompted by a beep signal, of which six were relevant for this study. These short questionnaires – taking approximately two minutes – were prompted semi-randomly within two-hour intervals at 08.00 – 09.59, 10.00 - 11.59, 12.00 - 13.59, 14.00 - 15.59, 16.00 - 17.59, and 18.00 - 19.59 (i.e. signal-contingent sampling). Each notification expired after 15 minutes to prevent reactivity (i.e. participants 'preparing

themselves' for the prompts) without being too inconvenient [23, 26].

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

The questionnaires assessed, in fixed order, symptom severity and affect. Fatigue – assessed as physical fatigue and mental fatigue – and dyspnoea were observed real-time using statements ("right now, I feel shortness of breath") that could be answered using 7-point Likert-type answers: 1 - 'strongly disagree' to 7 – 'strongly agree'. Cognitive function was assessed by asking for clarity of thought ("how is your 'thinking' (concentration, memory, attention) right now?") on a visual analogue scale (VAS): 0 - 'slow and difficult' to 10 - 'sharp and alert'. This scale was reversed for analysis (cognitive dysfunction), so that higher scores indicated higher severity. Pain was assessed first by asking if the participant experienced pain 'right now' (presence of pain). If affirmative, four additional prompts opened up to assess the severity of headache, joint pain, chest pain, and pain 'elsewhere in the body' or non-specific, which could be answered on four VAS: 0 - 'no pain' to 10 - 'worst imaginable pain'. However, as these pains varied too much between participants, the VAS were omitted from further analysis. Nevertheless, their pain courses over time per participant were visualised and are reported in Appendix S4. Affect was assessed using statements on five negative (anxious, gloomy, sad, irritable, and disappointed) and five positive feelings (excited, relaxed, satisfied, thankful, and joyful; e.g. "right now, I feel satisfied"), to be answered on a 7-point Likert-type scale: 1 – 'strongly disagree' to 7 – 'strongly agree'. Two mean scales of the five positive affect items and five negative affect items were created as intercorrelations within these constructs were very high (both: Cronbach's $\alpha = .96$). Additionally, a categorical variable (affect category) was made to indicate whether participants were predominantly positive (positive affect >4), predominantly negative (negative affect >4) or neither predominantly positive nor negative ('neutral'). All items were based on previously validated questionnaires or ESM studies [27-34].

Data analysis

ESM data consisted of observations (level 1) within days (level 2) within individuals (level 3). To make full use of the richness of these observations, data were primarily assessed visually. Observations were plotted for exploration per participant (affect and symptoms), per symptom by affect

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

category, and per symptom at the current time (t) with affect category of the previous time point (lagged t-1). The graphs were plotted in RStudio version 23.03.0 +386 [35].

Additionally, statistical models were used to support these interpretations. Statistical evidence for associations between symptoms were explored using personal averages (Person Mean) of each participant to account for potential within-person fluctuations. Spearman rank correlations (r_s) were used to account for non-parametric distributions and the small sample size. To assess potential associations between affect and symptoms structured as two levels (observations nested within participants), multilevel linear regression (MLR) models via the SPSS MIXED procedure were used. These models also account for randomly missing observations, which is common in ESM studies. The models accounted for participants (subjects) and timepoints (repeated measures), and were set up with restricted maximum likelihood estimations and first-order autoregressive (AR1) covariance structure, which was found to be best fitting according to the Akaike Information Criterion (AIC). As variables were measured with different scales, Z-scores were used for analysis and to retrieve standardised regression estimates. In the concurrent MLR models, each symptom was the outcome variable with either positive affect or negative affect as the fixed covariate. Due to a strong correlation between positive affect and negative affect $(r_s = -.82)$, these variables were examined separately in univariate MLR. To examine the prospective associations, positive and negative affect were lagged to the previous timepoint (t-1) in relation to the timepoint of the symptom. For these models, each first symptom measurement of the day was omitted, as the time between prior affect and symptom was too long (e.g. affect at T6 (e.g. 18.30) was adjusted to not predict an effect on fatigue next day at T7 (08.30)). Additionally, the outcome symptom was lagged t-1 and added as fixed covariate, to adjust for a continuance or residual experience of the symptom. Statistical significance was assessed using 95% confidence intervals and $\alpha < .05$. Standardised regression estimates were interpreted as small (>.1), medium (>.3) or large (>.5) effect size following Cohen's guidelines [36]. Descriptive statistics are presented in absolute number and percentages or median (Mdn) and interquartile range (IOR). IBM SPSS Statistics 28 was used for all statistical analyses.

Results

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Sample characteristics

After removing one participant with a compliance rate <30%, the final sample comprised 10 participants, who were between 48 and 76 (Mdn = 60, IQR = 9) years old and half of whom were women (n = 5). Five participants had one comorbidity, three participants had two or more and two had no comorbidities. All but two participants (80%) were overweight (Body Mass Index \geq 25; Mdn = 29.0, IQR = 14.6, Min = 22.0, Max = 41.8). Observations were made between 8 and 12 (Mdn = 10, IQR = 2) months after hospital discharge. Compliance rates of participants varied between 32 and 92% (Mdn = 63.5%, IQR = 40.1%), with in total 502 completed questionnaires.

Courses of post-COVID symptoms and affect

Visual assessment of the daily average symptom severity per participant (Fig 1) suggested that there were clear between-person differences in experiences of symptoms. Furthermore, physical and mental fatigue, dyspnoea and, to a lesser extent, cognitive dysfunction associated with each other over time on a daily level: an increase in one symptom co-occurred with an increase in the other. This interpretation was supported by correlational analyses of person mean severities (r_s between .37 and .85, p < .001; Table 1). For example, if a participant tends to experience physical fatigue, they also tend to experience cognitive dysfunction ($r_s(8) = .80$, p < .001). Although less obvious from the visual assessment, presence of pain likewise was weakly to moderately correlated to higher severity of other symptoms (r_s between .26 and .54, p < .001; Table 1). Visual assessment of the graphs (see Fig 2 for the course of physical fatigue per participant; see S2 for courses of mental fatigue, cognitive dysfunction, dyspnoea and pain per participant) revealed that symptoms fluctuated over time to various degrees. Cognitive dysfunction and pain showed the least variability and were mostly stable within participants. Aside from that, no clear temporal patterns were observed within participants. To illustrate, while physical fatigue often was lower in the afternoon for participant B, this was not necessarily the case every day (Fig 2).

Fig 1. Daily average symptom severity over 14 days for participants A – J. Pain presence was a dichotomous variable, with 1 =present and 0 =absent. Consequently, scores of e.g. 0.8 indicate that a participant did mostly but not always experience pain that day. See Fig 2 and Appendix S2 for more detailed insights in symptom courses.

Fig 2. Course of physical fatigue over 14 days with corresponding affect per participant A - J.

Table 1. Spearman correlations between symptoms at person mean level.

| | Physical | Mental | Cognitive | |
|------------------------------|----------|---------|-------------|----------|
| | fatigue | fatigue | dysfunction | Dyspnoea |
| Physical fatigue | - | | | |
| Mental fatigue | .76*** | - | | |
| Cognitive dysfunction | .73*** | .37*** | - | |
| Dyspnoea | .88*** | .53*** | .66*** | - |
| Pain presence | .25*** | .32*** | .27*** | .37*** |

207 *** = p < .001.

200

201

202

203

204

205

206

208

209

210

211

212

213

214

215

216

217

Affect was mostly stable within participants, with two participants (C and I, Fig 2; see S4 for courses of and interrelations between positive and negative affect per participant) predominantly experiencing negative affect. No evidence for emotional instability was found (S4).

Associations between affect and post-COVID symptoms

Concurrent associations

Overall, negative affect co-occurred with higher severity in all symptoms (Fig 2 and S2). Additionally, experiencing neither predominantly positive nor negative ('neutral') affect co-occurred with higher symptom severity. Conversely, predominantly positive affect co-occurred more often with

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

lower symptom severity. Pain seemed to be present regardless of affective tendencies in most participants. MLR models (Table 2) supported these assessments for all associations, and seem to suggest that both affects influence symptoms to a similar extent. For example, cognitive dysfunction was (almost) strongly and significantly associated negatively with positive affect ($\beta = -.46$) and positively with negative affect ($\beta = .51$).

Table 2. Overview of 10 univariate models of positive and negative affect as concurrent predictors of symptoms.

| Outcome |] | Positiv | e affect | Negative affect | | | |
|-----------------------|----|---------|----------|-----------------|------|------------|--|
| | ß | SE | 95%CI | ß | SE | 95%CI | |
| Physical fatigue | 67 | 0.04 | 75 to59 | .59 | 0.05 | .49 to .69 | |
| Mental fatigue | 59 | 0.05 | 69 to49 | .66 | 0.05 | .56 to .76 | |
| Cognitive dysfunction | 46 | 0.05 | 55 to36 | .51 | 0.06 | .39 to .62 | |
| Dyspnoea | 49 | 0.05 | 60 to39 | .37 | 0.07 | .24 to .50 | |
| Pain presence | 28 | 0.06 | 39 to16 | .24 | 0.07 | .10 to .38 | |

Standardised estimates of fixed covariate (either positive or negative affect) on outcome (symptom) in univariate multilevel linear regression models. All associations were statistically significant, p < .001. SE = standard error; 95%CI = 95% confidence intervals presented with respectively lower and upper limits.

Time-lagged associations

To explore whether symptoms were influenced by affect, positive and negative affect were lagged to the prior observation (t-1; visualisations in S3). As affect was relatively stable within participants, influences are inconclusive, but a change from positive to 'neutral' or negative affect might indicate a worsening of symptom severity (see e.g. Participant A). MLR models showed that although symptom severity often was a continuance or remnant of previous measurement – especially for the more stable symptoms such as cognitive dysfunction and presence of pain – both positive and negative

238

239

240

241

242

243

 244^{-}

245

246

247

248

affect still were significant but mostly weak predictors (Table 3), suggesting a small influence of affect on symptoms two hours later. Post-hoc analyses showed that, in line with the stable affect trajectories, time-lagged symptoms were not significant predictors of positive and negative affect two hours later.

Table 3. Overview of 10 multivariate models of positive and negative affect as time-lagged predictors of symptoms.

| Outcome | Predictor | Positive affect | | | Negative affect | | |
|------------------|---------------------------|-----------------|-------|------------|-----------------|------|------------|
| | | ß | SE | 95%CI | ß | SE | 95%CI |
| Physical fatigue | Affect t-1 | 31 | 0.05 | 41 to20 | .27 | 0.05 | .17 to .36 |
| | Physical fatigue t-1 | .46 | 0.05 | .36 to .57 | .51 | 0.05 | .41 to .60 |
| Mental fatigue | Affect t-1 | 18 | 0. 05 | 27 to08 | .28 | 0.05 | .19 to .38 |
| | Mental fatigue t-1 | .65 | 0. 05 | .56 to .74 | .54 | 0.05 | .45 to .64 |
| Cognitive | Affect t-1 | 14 | 0.04 | 21 to07 | .12 | 0.03 | .06 to .19 |
| dysfunction | Cognitive dysfunction t-1 | .82 | 0.04 | .75 to .89 | .85 | 0.03 | .78 to .91 |
| Dyspnoea | Affect t-1 | 22 | 0.04 | 31 to14 | .18 | 0.04 | .10 to .26 |
| | Shortness of t-1 | .61 | 0.05 | .52 to .71 | .67 | 0.04 | .58 to .75 |
| Pain presence | Affect t-1 | 09† | 0.03 | 15 to03 | .09† | 0.03 | .03 to .15 |
| | Pain t-1 | .82 | 0.03 | .76 to .89 | .83 | 0.03 | .76 to .90 |

Standardised estimates of fixed covariates (residual symptom and (either positive or negative) affect) on outcome (symptom) in multivariate multilevel linear regression models. The first preceding measurement of each predictor is represented as t-1. All associations were statistically significant at p <.001, except for \dagger : p = .006. SE = standard error; 95%CI = 95% confidence intervals presented with respectively lower and upper limits.

Discussion

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

This study explored the daily courses of and interrelations between affect and post-COVID-19 symptoms using an ESM approach. The main finding was that both positive and negative affect predicted symptom severity both concurrently and two hours later. Moreover, post-COVID-19 symptoms were found to fluctuate in severity both within and between days, and these severities fluctuated in co-occurrence with each other. This study showed that affect might play a role in the experience of post-COVID-19 symptom severity. This finding is in line with expectations that symptom severity is reduced in occurrence with and after positive affect, which is based on the Broaden-and-Build framework [14]. Moreover, the results are in accordance with previous findings on the relationships between trait affect and fatigue, dyspnoea and pain in other patient populations [17, 20, 21, 37]. Furthermore, they are comparable to findings in functional somatic syndromes such as fibromyalgia and chronic fatigue syndrome. For these syndromes, it has been reported that negative affective states and negative trait affect elicit increased symptom severity [22, 38], and that positive trait affect was associated with decreased symptom severity [22]. The present study suggests that similar affect – symptom relationships also exist in post-COVID-19 patients, and adds to the understanding that these relationships occur on a momentary level and have short-term persisting effects by showing that small to medium effects of positive and negative affect on symptoms can also be observed two hours later. Based on visual assessment, a difference in the relationship of positive and negative affect with symptom severity was observed. Negative affect was mostly consistent within two participants, while positive affect fluctuated more often and co-occurred with fluctuating symptom severity. This might suggest that there are important between- and within-individual differences. Previous findings in a general population showed that relationships between affect and somatic symptoms are better explained on a between-individual level by negative affect and on a within-individual level by positive affect [39]. Consequently, future studies on the relationships between affect or psychological issues (such as depression, anxiety or uncertainty) and post-COVID-19 symptoms should account for within-individual

differences that may be obscured by between-individual findings. Moreover, for treatment, this indicates

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

that different (affect-related) psychological approaches might be necessary and promising when dealing with symptom (self-)management.

Results also showed between- and within-individual differences in symptom severity. Not all participants experienced the same symptoms, and did not experience these symptoms at similar times. Moreover, no clear temporal trajectories could be observed in patients who experienced certain symptoms. For example, participants either experienced always severe or no dyspnoea, or the severity fluctuated for – as of yet – undetermined reasons (S2). Aside from small influences of affect, these fluctuations may be partially explained by exertion and daily activities, as previously explored for physical and mental fatigue in this sample [25].

Overall, present symptoms seemed to mostly co-occur, as they associated positively with each other over time within this sample—especially within somatic symptoms. Previously, it was shown using cross-sectional measures that many post-COVID-19 patients experience multiple symptoms (e.g. combinations of fatigue and pain, respiratory issues, and cognitive problems) at the same time, adding to the experienced disease burden [3]. The current study adds to the understanding that symptoms might influence each other's severity. Interestingly, these associations could also be beneficial for patients, as it suggests that successfully targeting one symptom (e.g. dyspnoea) for an intervention might also result in a reduction in other symptoms (e.g. physical fatigue and pain). Although the present study cannot provide full evidence for this, these general trends may indicate that in accordance with the Broadenand-Build framework and previous empirical findings that investigated sum score measures of symptoms [e.g., 39, 40], an overall increased well-being might similarly result in an overall decrease in symptom severity.

Taken together, our findings, especially on the role of positive affect, may serve as ground for exploration of an affect-based intervention, such as a positive psychological intervention (PPI). PPI have been found to be effective especially in chronic pain management and self-regulation [41, 42], and in reducing distress [43]. Therefore, they seem useful for post-COVID-19 symptom management. Additionally, an advantage of PPI is that they may provide participants with a sense of control over their rehabilitation. Perceived control was found to be severely impacted in post-COVID-19 patients [13]. Moreover, the effects of PPI are quickly noticeable by participants [see e.g. 44]. To make best use of

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

these interventions, tailoring to participants' needs might be necessary. Given the temporal association between (positive) affect and symptom severity, tailored adaptive interventions that identify specific times at which PPI could best take place (e.g. just-in-time adaptive interventions) seem promising. Future studies should explore the best targets for these times, or whether these interventions should even be time-based.

The strength of this study is the experience sampling methodology, which allowed for an indepth exploration of real-time assessed affect and symptom severity, increasing the reliability and ecological validity [23]. Moreover, by plotting participants' individual experiences of affect and symptoms over the day, a deep understanding was gained. Although this analytical strategy compensated for the small sample, the sample size can be seen as a limitation. Care should be taken to generalise the results. Evidence for temporal symptom patterns and stronger affect variability or instability may have arisen in a larger sample. Moreover, while the number of observations included was high, an average response rate of 60% is – while acceptable for ESM studies [23, 26] – rather low. Additionally, the sample was mostly homogeneous and consisted of patients with a relatively long course of post-COVID-19 syndrome following COVID-19 hospitalisation. Participants may have already learnt to live with their illness, as well as how to deal with certain negative emotions. Consequently, more recently diagnosed patients may experience more negative affect or higher symptom severity. Similarly, the effects of (the number of) vaccinations have not been accounted for. These have been shown to produce certain ameliorating effects on post-COVID-19 syndrome [45].

Conclusions

This study used an Experience Sampling Methodology to assess the temporal courses of and relations between affect and symptoms in the post-COVID-19 patients. It provided important insights in the momentary and prospective interactions between affect and post-COVID-19 symptoms. Both positive and negative affect play small but important roles in the severity of fatigue, cognitive dysfunction and dyspnoea and the presence of pain. Future studies should replicate and further explore

- 330 these associations in large and more diverse samples, to use insights for advanced psychological
- interventions for post-COVID-19 patients. 331

Acknowledgements

- 334 The authors thank Peter ten Klooster for his advice and support in data management and the statistical
- 335 analyses.

332

333

336

337

References

- 338 1. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the
- 339 long-term effects of COVID-19 2021 [updated November 11; cited 2023 May 22]. Available from:
- 340 https://www.nice.org.uk/guidance/ng188.
- 341 2. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of
- 342 Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and
- 343 Systematic Review. J Infect Dis. 2022;226(9):1593-607. doi: 10.1093/infdis/jiac136. PubMed PMID:
- 344 35429399; PubMed Central PMCID: PMCPMC9047189.
- 345 Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of 3.
- Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following 346
- 347 Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-15. doi:
- 348 10.1001/jama.2022.18931.
- 349 O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence 4.
- and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A 350
- 351 systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. Epub 20221201. doi:
- 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID: 352
- 353 PMCPMC9714474.
- 354 5. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et
- 355 al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv.

- 356 2021. Epub 2021/02/04. doi: 10.1101/2021.01.27.21250617. PubMed PMID: 33532785; PubMed
- Central PMCID: PMCPMC7852236 Company; the statements presented in the paper do not 357
- 358 necessarily represent the position of the company. The remaining authors have no competing interests
- 359 to declare.
- Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 360 6.
- 361 syndrome (PCS) and health-related quality of life (HRQoL)—A systematic review and meta-analysis.
- 362 J Med Virol. 2022;94(1):253-62. doi: 10.1002/jmv.27309.
- 363 7. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and
- 364 symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract.
- 365 2021;75(10):e14357-e. Epub 2021/06/02. doi: 10.1111/jjcp.14357. PubMed PMID: 33977626.
- 366 Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al. 8.
- Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living 367
- 368 systematic review. medRxiv. 2021:2021.06.03.21258317. doi: 10.1101/2021.06.03.21258317.
- 369 9. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising
- 370 long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. doi: 10.1136/bmjgh-
- 371 2021-005427. PubMed PMID: 34580069.
- 372 Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms 10.
- 373 after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services.
- 374 BMC Health Serv Res. 2020;20(1):1144. Epub 2020/12/22. doi: 10.1186/s12913-020-06001-y.
- 375 PubMed PMID: 33342437; PubMed Central PMCID: PMCPMC7750006.
- 376 11. Buttery S, Philip KEJ, Williams P, Fallas A, West B, Cumella A, et al. Patient symptoms and
- 377 experience following COVID-19: Results from a UK-wide survey. BMJ Open Respiratory Research.
- 378 2021;8(1). doi: 10.1136/bmjresp-2021-001075.
- 379 12. Humphreys H, Kilby L, Kudiersky N, Copeland R. Long COVID and the role of physical
- 380 activity: a qualitative study. BMJ Open. 2021;11(3):e047632. doi: 10.1136/bmjopen-2020-047632.
- 381 Schaap G, Wensink M, Doggen CJM, van der Palen J, Vonkeman HE, Bode C. "It Really Is 13.
- 382 an Elusive Illness"- Post-COVID-19 Illness Perceptions and Recovery Strategies: A Thematic
- Analysis. Int J Environ Public Health. 2022;19(20):13003. doi: 10.3390/ijerph192013003. 383

- 384 14. Fredrickson BL. The role of positive emotions in positive psychology. The broaden-and-build
- theory of positive emotions. Am Psychol. 2001;56(3):218-26. doi: 10.1037//0003-066x.56.3.218. 385
- 386 PubMed PMID: 11315248; PubMed Central PMCID: PMCPMC3122271.
- 387 15. Fredrickson BL. The broaden–and–build theory of positive emotions. Philosophical
- Transactions of the Royal Society of London Series B: Biological Sciences. 2004;359(1449):1367-77. 388
- 389 doi: 10.1098/rstb.2004.1512.
- 390 16. Frijda NH. The emotions. Paris, France: Editions de la Maison des Sciences de l'Homme;
- 391 1986. xii, 544-xii, p.
- von Leupoldt A, Denutte Y. Affective traits, states, and breathlessness. Curr Opin Support 392 17.
- 393 Palliat Care. 2020;14(3):182-9. doi: 10.1097/spc.000000000000506. PubMed PMID: 01263393-
- 394 202009000-00006.
- 395 Finan PH, Garland EL. The role of positive affect in pain and its treatment. Clin J Pain. 18.
- 396 2015;31(2):177-87. doi: 10.1097/AJP.0000000000000092.
- 397 19. Hanssen MM, Peters ML, Boselie JJ, Meulders A. Can positive affect attenuate (persistent)
- 398 pain? State of the art and clinical implications. Current Rheumatology Reports. 2017;19(12):80. doi:
- 399 10.1007/s11926-017-0703-3.
- 400 20. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, Reid MC. Positive affect and chronic
- 401 pain: a preregistered systematic review and meta-analysis. PAIN. 2020;161(6):1140-9. doi:
- 402 10.1097/j.pain.0000000000001828. PubMed PMID: 00006396-202006000-00004.
- 403 21. Strebkova R. Subjective Well-Being and its Impact on Cancer-Related Fatigue in Patients
- Undergoing Radiotherapy and Long-Term Survivors. Acta Medica Bulgarica. 2020;47(4):18-23. doi: 404
- 405 doi:10.2478/amb-2020-0040.
- 406 22. Toussaint LL, Vincent A, McAllister SJ, Oh TH, Hassett AL. A comparison of fibromyalgia
- 407 symptoms in patients with Healthy versus Depressive, Low and Reactive affect balance styles. Scand J
- 408 Pain. 2014;5(3):161-6. doi: 10.1016/j.sjpain.2014.05.001.
- 409 Myin-Germeys I, Kuppens P, editors. The open handbook of experience sampling 23.
- 410 methodology: A step-by-step guide to designing, conducting, and analyzing ESM studies. 2nd ed.
- 411 Leuven: Center for Research on Experience Sampling and Ambulatory Methods Leuven: 2022.

- 412 24. Aaronson NK, Muller M, Cohen PDA, Essink-Bot M-L, Fekkes M, Sanderman R, et al.
- Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in 413
- 414 Community and Chronic Disease Populations. J Clin Epidemiol. 1998;51(11):1055-68. doi:
- 415 10.1016/S0895-4356(98)00097-3.
- 416 Wensink M, Schaap G, ten Klooster PM, Doggen CJM, van der Palen J, Vonkeman HE, et al. 25.
- 417 Physical and mental fatigue in post-COVID syndrome and their associations over time: A small-
- sample ESM-study to explore fatigue, quality of sleep and behaviours. J Psychosom Res. 418
- 419 2023;164:111084. doi: https://doi.org/10.1016/j.jpsychores.2022.111084.
- 420 26. Conner TS, Lehman BJ. Launching a Study in Daily Life. In: Mehl M, Conner TS, editors.
- 421 Handbook of Research Methods for Studying Daily Life. New York: Guilford Press; 2012. p. 88 - 107.
- 422 27. Brys ADH, Stifft F, Van Heugten CM, Bossola M, Gambaro G, Lenaert B. Unraveling Fatigue
- 423 in Hemodialysis Patients: Comparing Retrospective Reports to Real-Time Assessments With an
- 424 mHealth Experienced Sampling Method. J Pain Symptom Manage. 2020;60(6):1100-8.e2. doi:
- 425 10.1016/j.jpainsymman.2020.06.042.
- 426 28. Dietvorst E, Hiemstra M, Maciejewski D, van Roekel E, Bogt Tt, Hillegers M, et al. Grumpy
- 427 or depressed? Disentangling typically developing adolescent mood from prodromal depression using
- 428 experience sampling methods. J Adolesc. 2021;88:25-35. doi: 10.1016/j.adolescence.2021.01.009.
- 429 29. Jean FAM, Sibon I, Husky M, Couffinhal T, Swendsen J. Feasibility and validity of
- 430 Ecological Momentary Assessment in patients with acute coronary syndrome. BMC Cardiovasc
- 431 Disord. 2020;20(1). doi: 10.1186/s12872-020-01774-w.
- 432 30. Kratz AL, Braley TJ, Foxen-Craft E, Scott E, Murphy JF, Murphy SL. How Do Pain, Fatigue,
- 433 Depressive, and Cognitive Symptoms Relate to Well-Being and Social and Physical Functioning in the
- 434 Daily Lives of Individuals With Multiple Sclerosis? Arch Phys Med Rehabil. 2017;98(11):2160-6.
- 435 doi: 10.1016/j.apmr.2017.07.004.
- 436 31. Lenaert B. Neijmeijer M. van Kampen N. van Heugten C. Ponds R. Poststroke Fatigue and
- Daily Activity Patterns During Outpatient Rehabilitation: An Experience Sampling Method Study. 437
- Arch Phys Med Rehabil. 2020;101(6):1001-8. doi: 10.1016/j.apmr.2019.12.014. PubMed PMID: 438
- 439 WOS:000543030600008.

- 440 32. Maes IHL, Delespaul PAEG, Peters ML, White MP, van Horn Y, Schruers K, et al. Measuring
- 441 Health-Related Quality of Life by Experiences: The Experience Sampling Method. Value Health.
- 442 2015;18(1):44-51. doi: 10.1016/j.jval.2014.10.003.
- 443 33. Romano KA, Heron KE, Smith KE, Crosby RD, Engel SG, Wonderlich SA, et al. Somatic
- symptoms and binge eating in women's daily lives. J Psychosom Res. 2020;135. doi: 444
- 445 10.1016/j.jpsychores.2020.110161.
- 446 34. Worm-Smeitink M, Monden R, Groen RN, van Gils A, Bekhuis E, Rosmalen J, et al. Towards
- 447 personalized assessment of fatigue perpetuating factors in patients with chronic fatigue syndrome
- 448 using ecological momentary assessment: A pilot study. J Psychosom Res. 2021;140. doi:
- 449 10.1016/j.jpsychores.2020.110296.
- 450 35. Posit Team. RStudio: Integrated Development Environment for R: Posit Software, PBC; 2023.
- 451 Available from: https://posit.co/.
- 452 Cohen J. Statistical Power Analysis for the Behavioural Sciences: Academic Press, New York; 36.
- 453 1988.
- 454 37. Zautra AJ, Fasman R, Parish BP, Davis MC. Daily fatigue in women with osteoarthritis,
- 455 rheumatoid arthritis, and fibromyalgia. Pain. 2007;128(1):128-35. doi: 10.1016/j.pain.2006.09.004.
- 456 38. Van Den Houte M, Bogaerts K, Van Diest I, De Bie J, Persoons P, Van Oudenhove L, et al.
- 457 Inducing Somatic Symptoms in Functional Syndrome Patients: Effects of Manipulating State Negative
- 458 Affect. Psychosom Med. 2017;79(9):1000-7. doi: 10.1097/psy.00000000000527. PubMed PMID:
- 459 00006842-201711000-00007.
- 460 39. Schenk HM, Bos EH, Slaets JPJ, de Jonge P, Rosmalen JGM. Differential association between
- 461 affect and somatic symptoms at the between- and within-individual level. Br J Health Psychol.
- 462 2017;22(2):270-80. doi: 10.1111/bjhp.12229.
- 463 40. Clark LA, Watson D. Mood and the mundane: relations between daily life events and self-
- reported mood. J Pers Soc Psychol. 1988;54(2):296-308. doi: 10.1037//0022-3514.54.2.296. PubMed 464
- PMID: 3346815. 465

- 41. Braunwalder C, Müller R, Glisic M, Fekete C. Are Positive Psychology Interventions 466
- 467 Efficacious in Chronic Pain Treatment? A Systematic Review and Meta-Analysis of Randomized
- 468 Controlled Trials. Pain Med. 2021;23(1):122-36. doi: 10.1093/pm/pnab247.
- 469 42. Iddon JE, Dickson JM, Unwin J. Positive Psychological Interventions and Chronic Non-
- Cancer Pain: A Systematic Review of the Literature. Int J Appl Posit Psychol. 2016;1(1):133-57. doi: 470
- 471 10.1007/s41042-016-0003-6.
- 472 43. Chakhssi F, Kraiss JT, Sommers-Spijkerman M, Bohlmeijer ET. The effect of positive
- 473 psychology interventions on well-being and distress in clinical samples with psychiatric or somatic
- 474 disorders: a systematic review and meta-analysis. BMC Psychiatry, 2018;18(1):211. Epub 20180627.
- 475 doi: 10.1186/s12888-018-1739-2. PubMed PMID: 29945603; PubMed Central PMCID:
- 476 PMCPMC6020379.

484

485

- 477 Geschwind N, Arntz A, Bannink F, Peeters F. Positive cognitive behavior therapy in the 44.
- 478 treatment of depression: A randomized order within-subject comparison with traditional cognitive
- 479 behavior therapy. Behav Res Ther. 2019;116:119-30. Epub 20190309. doi:
- 480 10.1016/j.brat.2019.03.005. PubMed PMID: 30897464.
- 45. 481 Tofarides AG, Christaki E, Milionis H, Nikolopoulos GK. Effect of Vaccination against
- SARS-CoV-2 on Long COVID-19: A Narrative Review. Life (Basel). 2022;12(12). Epub 20221208. 482
- 483 doi: 10.3390/life12122057. PubMed PMID: 36556422; PubMed Central PMCID: PMCPMC9785763.

Supporting information

- 486 S1. Morning and momentary questionnaires
- 487 S2. Visualisations of courses of symptoms with concurrent affect
- 488 S3. Visualisations of courses of symptoms with time-lagged affect
- 489 S4. Visualisations of courses of affect and of specified pains




Fig 1

